INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA
Authors:
- Jose M. Ruiz-MorenoJRJose M. Ruiz-Moreno
- Javier A. MonteroJMJavier A. Montero
- Javier AraizJAJavier Araiz
- Luis AriasLALuis Arias
- Alfredo García-LayanaAGAlfredo García-Layana
- Angela CarneiroACAngela Carneiro
- Marta S. FigueroaMFMarta S. Figueroa
- Rufino SilvaRSRufino Silva
- 1 December 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Retina
- Vol. 35 (12) , 2450-2456
Abstract
To report the visual outcome after 6-year follow-up in highly myopic eyes with choroidal neovascularization treated with anti-vascular endothelial growth factor drugs. Retrospective, nonrandomized, multicenter, consecutive, and interventional case series. Seventy-eight patients were treated with intravitreal bevacizumab and 19 with ranibizumab. Mean age of the patients was 56.5 years (SD, 13.3). The average number of letters read was 56.7 (SD, 19.0) at baseline; 65.7 (SD, 18.4) at 12 months; 63.6 (SD, 20.6) at 24 months; 62.4 (SD, 21.4) at 36 months; 60.6 (SD, 22.0) at 48 months; 58.9 (SD, 22.9) at 60 months, and 58.4 (SD, 22.7) at 72 months (P < 0.01, between initial vs. 12, 24, and 36 months; P = 0.07, 0.3, and 0.5 between initial vs. 48, 60, and 72 months, respectively; Student's t-test paired data). The mean total number of intravitreal injections was 3.3 (SD, 2.3; range, 1-9). Bevacizumab and ranibizumab are effective therapies and show similar clinical effects in myopic eyes with choroidal neovascularization. Visual acuity gain is maintained at a 3-year follow-up. The improvement is no longer statistically significant at Years 4, 5, and 6.Keywords
This publication has 32 references indexed in Scilit:
- Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcomeBritish Journal of Ophthalmology, 2013
- Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR studyEye, 2013
- Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopiaBritish Journal of Ophthalmology, 2012
- TWO-YEAR OUTCOMES OF INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN JAPANESE PATIENTS WITH PATHOLOGIC MYOPIARetina, 2012
- Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study resultsCanadian Journal of Ophthalmology, 2012
- INTRAVITREAL RANIBIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATIONRetina, 2010
- Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcomeBritish Journal of Ophthalmology, 2008
- SHORT-TERM EFFICACY AND SAFETY OF INTRAVITREAL RANIBIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATIONRetina, 2008
- Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopiaBritish Journal of Ophthalmology, 2007
- Bevacizumab suppresses choroidal neovascularisation caused by pathological myopiaBritish Journal of Ophthalmology, 2005